Mangalam Drugs & Organics Limited , a prominent player in the pharmaceutical industry, has recently been the subject of a significant share pledge transaction. Shree Kishoriju Trading and Investment Private Limited, a key stakeholder in the company, has pledged a substantial portion of its holdings as security for debt.

Share Pledge Details

Shree Kishoriju Trading and Investment Private Limited has created a pledge on 877,000 shares of Mangalam Drugs & Organics Limited. This pledge was established on October 30, 2021, in favor of Badjate Stock Broking Private Limited. The pledged shares represent 5.54% of Mangalam Drugs' total share capital.

Impact on Shareholding

Following this transaction, Shree Kishoriju Trading's total encumbered holdings in Mangalam Drugs have increased to 1,098,515 shares. This figure now accounts for 6.94% of the company's share capital, indicating a significant portion of their investment is now tied to debt obligations.

Regulatory Compliance

In adherence to regulatory requirements, Director Radhika Ajay Dhoot made the necessary disclosure to the stock exchanges where Mangalam Drugs is listed. This transparency ensures that all stakeholders are informed about significant changes in share pledging that could potentially impact the company's ownership structure.

Company Update

While not directly related to the share pledge, it's worth noting that Mangalam Drugs & Organics Limited has recently made changes to its corporate governance structure. According to the latest LODR (Listing Obligations and Disclosure Requirements) data:

• The company's Board of Directors approved the appointment of Ragini Chokshi & Co. as Secretarial Auditors.
• Ragini Chokshi & Co., a firm of Practicing Company Secretaries with over 35 years of experience, has been appointed for a term of five consecutive years.
• This appointment is subject to shareholder approval at the upcoming Annual General Meeting.

These corporate governance measures, while separate from the share pledge event, demonstrate Mangalam Drugs' commitment to maintaining robust internal controls and compliance with regulatory standards.

The share pledge by Shree Kishoriju Trading and Investment Private Limited represents a significant financial maneuver, potentially impacting the ownership dynamics of Mangalam Drugs & Organics Limited. Investors and market watchers will likely keep a close eye on any further developments related to this transaction and its implications for the company's financial structure.

Mangalam Drugs & Organics Limited , a prominent player in the pharmaceutical industry, has taken a significant step towards corporate restructuring. The company's proposed merger scheme received overwhelming support from its unsecured creditors during a Tribunal Convened Meeting (TCM) held on August 12, 2025.

Merger Approval Details

The TCM, conducted via video conferencing, saw a strong turnout of unsecured creditors voting on the resolution for the Scheme of Merger by Absorption. The scheme proposes the merger of Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited with Mangalam Drugs and Organics Limited.

Voting Results

The voting results demonstrated a resounding approval for the merger:

Out of the 80 total unsecured creditors eligible to vote as of the December 31, 2024 cut-off date, 36 participated in the meeting. The strong support for the merger is evident, with 98.46% of the voting value backing the resolution.

Scrutinizer's Report

Shri Venugopal Prasad Rao, appointed as the scrutinizer by the National Company Law Tribunal (NCLT) Mumbai Bench, oversaw the voting process. The scrutinizer's report confirmed the validity of the voting procedure, which included both remote e-voting and e-voting during the meeting.

Management's Authorization

Following the successful vote, the Board of Directors of Mangalam Drugs & Organics Limited has been authorized to take necessary steps to implement the merger scheme. This includes accepting any modifications or conditions that may be imposed by regulatory authorities during the sanction process.

Implications and Next Steps

The strong backing from unsecured creditors marks a crucial milestone in Mangalam Drugs & Organics' corporate restructuring efforts. The merger is expected to streamline operations, potentially leading to improved efficiencies and synergies across the merged entities.

The company will now proceed to seek final approvals from the NCLT and other relevant statutory bodies to complete the merger process. Shareholders and stakeholders will be keenly watching the developments as the company moves forward with its strategic restructuring plans.

As Mangalam Drugs & Organics Limited progresses with this significant corporate action, it reinforces the company's commitment to growth and value creation for all its stakeholders in the competitive pharmaceutical landscape.